Senetek Completes Zeatin Preclinical Studies; Clinical Trials Underway

Senetek has completed preclinical studies assessing the safety and efficacy of its patented cytokinin, Zeatin, as a topical skin anti-aging treatment.

Senetek's lead skincare compound, Kinetin, has been widely accepted as a successful treatment for anti-aging, having been proven to be highly effective in clinical trials at a leading University. Zeatin appears to be complementary to Kinetin having its origin from RNA while Kinetin is derived from DNA.

Zeatin preclinical studies were conducted at five separate research facilities over a two year period.